Рак молочной железы

Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer

Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer Bioengineer.org

Oncology Experts Highlight Landmark FDA Approval of Camizestrant in HR+/HER2- Advanced Breast Cancer

Oncology Experts Highlight Landmark FDA Approval of Camizestrant in HR+/HER2- Advanced Breast Cancer oncodaily.com

FDA Approves Camizestrant Despite Negative ODAC Vote: What It Means for ESR1-Mutated Breast Cancer

FDA Approves Camizestrant Despite Negative ODAC Vote: What It Means for ESR1-Mutated Breast Cancer Onco'Zine

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Business Wire

FDA OKs Etcamah for advanced breast cancer

The FDA has granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. The approval for camizestrant (Etcamah, AstraZeneca) is dependent on the detection of an ESR1 mutation during aromatase…

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

FDA Grants Accelerated Approval to a New Breast Cancer Treatment The Well News

<![CDATA[FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer]]>

AI May Help Identify Breast Cancers Missed by Mammograms, But Clinical Benefit Remains Uncertain - UCLA Health - Oncodaily

AI May Help Identify Breast Cancers Missed by Mammograms, But Clinical Benefit Remains Uncertain - UCLA Health Oncodaily

Angela Hernandez Shares Her Breast Cancer Story | BCRF

Angela Hernandez Shares Her Breast Cancer Story | BCRF Breast Cancer Research Foundation | BCRF

Interpreting Frontline ADC Trial Data in Metastatic Triple-Negative Breast Cancer

Interpreting Frontline ADC Trial Data in Metastatic Triple-Negative Breast Cancer Oncology Nursing News

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms, and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram, but there are still many significant limitations…

ИИ может помочь выявить рак, пропущенный при маммографии - Наука Mail

ИИ может помочь выявить рак, пропущенный при маммографии Наука Mail

Memory tests may be limited after breast cancer chemotherapy

Women who received chemotherapy for breast cancer had lower performance in narrative memory tasks and greater cognitive workloads than women with no history of breast cancer, according to data published in Translational Neuroscience. Yet both groups had similar performance in tasks involving verbal paired associates…

Matthew Kurian: KYSCO Advances Breast Cancer Education for Community Oncologists - Oncodaily

Matthew Kurian: KYSCO Advances Breast Cancer Education for Community Oncologists Oncodaily

Breast cancer rates are rising among women under 40: why tailored treatment is needed for every age group - Il Sole 24 ORE

Breast cancer rates are rising among women under 40: why tailored treatment is needed for every age group Il Sole 24 ORE